Veracyte

Veracyte Receivables

The Accounts Receivable of Veracyte (VCYT) as of Oct 14, 2026 is 44.66 M USD. In the previous year, Accounts Receivable was 46.53 M USD — a change of -4.01% (lower).

Receivables

44.66 MUSD

YoY

-4.01%

Last updated:

Accounts Receivable of Veracyte is 2025 44.66 M USD. Accounts Receivable of Veracyte was 2024 46.53 M USD. It decreases by -4.01% lower compared to the previous year.

The Veracyte Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
13.20 M USD
Jan 1, 2019
19.30 M USD
Jan 1, 2020
18.50 M USD
Jan 1, 2021
41.50 M USD
Jan 1, 2022
44.00 M USD
Jan 1, 2023
40.38 M USD
Jan 1, 2024
46.53 M USD
Jan 1, 2025
44.66 M USD
The Veracyte Receivables history
YEARReceivablesYoY
44.66 MUSD-4.01%
46.53 MUSD+15.22%
40.38 MUSD-8.23%
44.00 MUSD+6.02%
41.50 MUSD+124.32%
18.50 MUSD-4.15%
19.30 MUSD+46.21%
13.20 MUSD+3.94%
12.70 MUSD+44.32%
8.80 MUSD+151.43%
3.50 MUSD+12.90%
3.10 MUSD—
Access this data via the Eulerpool API

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

Accounts Receivable of Veracyte is 44.66 M USD in 2025.

Accounts Receivable of Veracyte changed from 46.53 M USD to 44.66 M USD, representing a -4.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Veracyte since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Veracyte historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Veracyte

All Key Metrics — Veracyte